Abstract
Background: Non-small-cell carcinoma of the lung has long been considered a chemotherapeutically resistant neoplasm. Newer agents and combinations are being tested. Methods: The authors have reviewed data on recent and active phase I and phase II trials of several new agents and combinations. Results: New drugs that affect both response rates and survival include vinorelbine, paclitaxel, docetaxel, gemcitabine, topotecan, and irinotecan. Conclusions: The advent of several relatively well-tolerated agents that alone have beneficial effects in advanced non-small-cell lung cancer provides reasonable hope that more effective drug combinations will soon be available for this disease.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 317-325 |
| Number of pages | 9 |
| Journal | Cancer Control |
| Volume | 4 |
| Issue number | 4 |
| State | Published - 1997 |
Fingerprint
ASJC Scopus subject areas
- Oncology
Cite this
New agents in the management of non-small-cell lung cancer. / Chiappori, A.; Devore, R. F.; Johnson, D. H.
In: Cancer Control, Vol. 4, No. 4, 1997, p. 317-325.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - New agents in the management of non-small-cell lung cancer
AU - Chiappori, A.
AU - Devore, R. F.
AU - Johnson, D. H.
PY - 1997
Y1 - 1997
N2 - Background: Non-small-cell carcinoma of the lung has long been considered a chemotherapeutically resistant neoplasm. Newer agents and combinations are being tested. Methods: The authors have reviewed data on recent and active phase I and phase II trials of several new agents and combinations. Results: New drugs that affect both response rates and survival include vinorelbine, paclitaxel, docetaxel, gemcitabine, topotecan, and irinotecan. Conclusions: The advent of several relatively well-tolerated agents that alone have beneficial effects in advanced non-small-cell lung cancer provides reasonable hope that more effective drug combinations will soon be available for this disease.
AB - Background: Non-small-cell carcinoma of the lung has long been considered a chemotherapeutically resistant neoplasm. Newer agents and combinations are being tested. Methods: The authors have reviewed data on recent and active phase I and phase II trials of several new agents and combinations. Results: New drugs that affect both response rates and survival include vinorelbine, paclitaxel, docetaxel, gemcitabine, topotecan, and irinotecan. Conclusions: The advent of several relatively well-tolerated agents that alone have beneficial effects in advanced non-small-cell lung cancer provides reasonable hope that more effective drug combinations will soon be available for this disease.
UR - http://www.scopus.com/inward/record.url?scp=0030776238&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030776238&partnerID=8YFLogxK
M3 - Article
VL - 4
SP - 317
EP - 325
JO - Cancer Control
JF - Cancer Control
SN - 1073-2748
IS - 4
ER -